发明名称 |
ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR REDUCING THE RISK OF MORTALITY IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION |
摘要 |
According to the present invention it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present invention said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM that is located in the N-terminal part (aa 1-21) of adrenomedullin, (see FIG. 2). In another preferred embodiment said anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold recognizes and binds to the N-terminal end (aa1) of adrenomedullin. N-terminal end means that the amino acid 1, that is "Y" of SEQ ID No. 21 or 23, is mandatory for antibody binding. The anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold would neither bind N-terminal extended nor N-terminal modified Adrenomedullin nor N-terminal degraded Adrenomedullin in said preferred embodiment.
|
申请公布号 |
US2013195874(A1) |
申请公布日期 |
2013.08.01 |
申请号 |
US201213679281 |
申请日期 |
2012.11.16 |
申请人 |
ADRENOMED AG;ADRENOMED AG |
发明人 |
BERGMANN ANDREAS |
分类号 |
A61K39/395;A61K31/137;A61K38/17;A61K45/06 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|